Biotechs As In-Licensers
A closer look at the trend in biotech (top tier, and others) and specialty pharma in-licensing of clinical stage products.
You may also be interested in...
Do in-licensing-focused specialty pharmas spell tougher competition for Big Pharma, traditionally the biggest customer for late-stage product licenses?
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.